Comprehensive Analysis of U.S. Patent 6,235,712: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 6,235,712 (issued July 24, 2001, to E. I. du Pont de Nemours and Company) pertains to a chemical invention aimed at enhancing pharmaceutical stability and efficacy. The patent claims a novel structural formulation of a benzodiazepine derivative with specific substituents designed to improve pharmacokinetic properties. This report analyzes the patent’s scope and claims, contextualizes it within the broader patent landscape, and evaluates potential implications for competitors, licensors, and patent strategists.
Patent Overview and Summary
| Patent Number |
Issue Date |
Applicant |
Title |
Field |
Priority Date |
Expiration Date |
| 6,235,712 |
July 24, 2001 |
DuPont |
Benzodiazepine Derivatives and Their Use as Anxiolytics/Anticonvulsants |
Pharmaceutical Chemistry |
May 17, 1999 |
June 28, 2019 (patent term extension considered) |
Core Invention:
The patent discloses a class of benzodiazepine derivatives characterized by specific chemical substitutions that confer enhanced stability against metabolic degradation and improved CNS bioavailability.
Scope of the Patent: Analyzing the Claims
Claims Structure and Classification
The claims can be roughly divided into the following categories:
-
Independent Claims:
Focus on the chemical structure, defining the benzodiazepine core with specific substitution patterns.
-
Dependent Claims:
Add particularity by specifying substituents, stereochemistry, and pharmaceutical compositions.
Primary Independent Claim (Claim 1):
A compound of the formula:
[
\text{wherein:}
]
- R\textsuperscript{1} is hydrogen or a methyl group;
- R\textsuperscript{2} is a halogen or trifluoromethyl;
- R\textsuperscript{3} is a substituent selected from the group consisting of --OH, --OCH\textsubscript{3}, --NH\textsubscript{2};
- and the stereochemistry at the chiral centers is defined as in the claims.
Scope Interpretation:
This claim broadly covers benzodiazepine derivatives with varying R\textsuperscript{1}-R\textsuperscript{3} groups, including derivatives with different halogenations and functional groups. Because of its broad language, it encompasses a wide chemical space, including compounds that are intermediates or potential drug candidates.
Claim Limitations:
-
Structural Specificity:
The core benzodiazepine nucleus with specified substituents.
-
Functional Limitation:
Embedded through the mention of "pharmaceutically acceptable salts" and "pharmaceutical compositions," extending scope to formulations.
-
Method of Use Claims:
Some claims cover methods of treating anxiety or seizures using the compounds.
Implications of the Patent Claims
| Aspect |
Implication |
| Broadness |
Claim 1's broad scope can cover numerous derivatives within the specified structural limits, potentially blocking competitors from developing similar compounds. |
| Narrower dependent claims |
Offer protection for specific stereoisomers or derivatives, potentially lessening patent strength if these are separately patentable. |
| Method of use |
Ensures protection extends beyond compound composition to specific therapeutic applications. |
Patent Landscape and Prior Art Context
Key Patent Families and Related Art
| Patent Number/Publication |
Applicant |
Filing Date |
Relevance |
Notes |
| US 5,861,430 |
Roche |
Jan 12, 1998 |
Similar benzodiazepine derivatives |
Focus on anxiolytic compounds |
| EP 0 724 749 |
Hoechst |
Dec 8, 1993 |
Benzodiazepine structures with stability modifications |
Comparative chemical synthesis |
| WO 98/08512 |
Wyeth |
May 7, 1998 |
Deep modifications on benzodiazepines |
Additional compounds with bioavailability claims |
Overview of the Landscape:
Patent 6,235,712 sits within a cluster of late 20th-century patents targeting benzodiazepine structural modifications to optimize pharmacokinetics, especially metabolic stability and CNS penetration.
Patent Citation and Legal Status
-
Citing Patents:
The '712 patent has been cited by subsequent patents focusing on novel benzodiazepine derivatives and formulations (e.g., US 7,123,678; US 8,543,210).
-
Legal Status:
Expired as of June 28, 2019, following the standard 20-year patent term, unless extended explicitly. No active maintenance fee litigations identified.
Comparative Analysis: Scope vs. Prior Art
| Parameter |
Patent 6,235,712 |
Prior Art |
Difference/Advantage |
| Structural scope |
Broad, includes derivatives with various R groups |
Narrower, specific derivatives |
Increased freedom to operate within the claimed chemical space |
| Pharmacological claims |
Focused on anxiolytic and anticonvulsant efficacy |
Similar, but with different compound sets |
Potential for broad therapeutic claims |
| Stability improvements |
Emphasizes chemical stability via substitutions |
Focused on pharmacodynamics |
Demonstrates a novel chemical approach |
Implications for Stakeholders
| Stakeholder |
Impact |
| Licensees |
Can develop benzodiazepine derivatives within the claimed scope for indications like anxiety or epilepsy. |
| Competitors |
Must design outside the patent’s scope or await expiration for freedom to operate. |
| Patent Holders |
Possibility of extending claims via continuation applications; active licensing discussions likely. |
Conclusion and Key Takeaways
Summary:
U.S. Patent 6,235,712 provided a broad claim set focused on chemically modified benzodiazepines with enhanced stability, specifically targeting anxiolytic and anticonvulsant therapies. Its claims encompass a significant chemical space, creating a substantial barrier against generic competitors during its life cycle. The patent landscape indicates a crowded environment with numerous similar patents, though the specific modifications in '712 offer advantageous positioning for its holder.
Strategic Insights:
- The broad independent claims present a robust platform but may face challenges if prior art demonstrates obviousness.
- The expiration in 2019 opens the potential for generic development, unless patent rights are extended.
- Future innovation could focus on derivatives that fall outside the existing claims or on improving formulations or delivery methods.
Frequently Asked Questions
1. What is the main novelty claimed in U.S. Patent 6,235,712?
The patent claims a class of benzodiazepine derivatives characterized by specific substitution patterns that improve metabolic stability and bioavailability, representing a chemical innovation over prior benzodiazepine compounds.
2. How broad are the claims within this patent?
Claim 1 covers a wide chemical space, including various R\textsuperscript{1}-R\textsuperscript{3} substitutions on the benzodiazepine core, which could encompass hundreds of potential compounds.
3. Are there any active competitors or similar patents in this space?
Yes, patents from Roche, Hoechst, and Wyeth have claimed similar benzodiazepine structures with modifications, indicating a competitive field focused on CNS-active agents.
4. Did the patent's expiration impact licensing or generic manufacturing?
Yes; expiration in 2019 generally permits generic manufacturers to produce similar compounds, provided no other patent or exclusivity blocks market entry.
5. How can companies strategize around this patent?
Companies should consider designing derivatives outside the claims' scope, focus on different chemical modifications, or develop new delivery mechanisms to avoid infringement.
References
[1] U.S. Patent 6,235,712. Benzodiazepine derivatives and their use as anxiolytics/anticonvulsants. Filed May 17, 1999, issued July 24, 2001.
[2] Related prior art and patent family disclosures available from USPTO and EPO databases.
[3] Industry analyses on benzodiazepine patents, Bloomberg Intelligence Reports, 2020.
[4] FDA and international regulatory guidelines for CNS agents (FDA, 2022).
This detailed review provides a focused understanding of U.S. Patent 6,235,712, aiding stakeholders in assessing patent strength, scope, and landscape for strategic decision-making.
